Nanobiotix S.A. (EPA:NANO)
France · Delayed Price · Currency is EUR 46.18
+2.08 (4.72%)
May 14, 2026, 5:35 PM CET
Nanobiotix Revenue
In the year 2025, Nanobiotix had annual revenue of 32.59M EUR. Nanobiotix had revenue of 5.96M in the half year ending December 31, 2025, a decrease of -81.91%.
Revenue
32.59M
Revenue Growth
n/a
P/S Ratio
65.62
Revenue / Employee
325.93K
Employees
100
Market Cap
2.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.59M | 39.78M | - |
| Dec 31, 2024 | -7.19M | -43.40M | - |
| Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 135.00K | 5.37% |
| Dec 31, 2020 | 2.51M | -29.00K | -1.14% |
| Dec 31, 2019 | 2.54M | -938.00K | -26.96% |
| Dec 31, 2018 | 3.48M | -242.53K | -6.52% |
| Dec 31, 2017 | 3.72M | -1.70M | -31.36% |
| Dec 31, 2016 | 5.42M | 1.41M | 35.03% |
| Dec 31, 2015 | 4.02M | 1.24M | 44.91% |
| Dec 31, 2014 | 2.77M | 2.59M | 1,398.23% |
| Dec 31, 2013 | 184.94K | -785.67K | -80.95% |
| Dec 31, 2012 | 970.61K | -389.70K | -28.65% |
| Dec 31, 2011 | 1.36M | 225.46K | 19.87% |
| Dec 31, 2010 | 1.13M | -1.63M | -59.00% |
| Dec 31, 2009 | 2.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 174.66M |
| Genfit | 65.43M |
| Cellectis | 65.14M |
| MedinCell | 32.44M |
| Transgene | 7.21M |
| Inventiva | 6.76M |
| Sensorion | 5.81M |
| DBV Technologies | 4.97M |
Nanobiotix News
- 9 days ago - Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment - TheFly
- 9 days ago - Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study - GlobeNewsWire
- 13 days ago - Nanobiotix price target raised to $30 from $3.50 at UBS - TheFly
- 24 days ago - Nanobiotix Announces Positive Preclinical Data For Nanoprimer In LNP-DNA Delivery - Nasdaq
- 24 days ago - Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology - GlobeNewsWire
- 4 weeks ago - Nanobiotix price target raised to EUR 34 from EUR 32 at H.C. Wainwright - TheFly
- 5 weeks ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 6 weeks ago - Nanobiotix price target raised to $36 from $26 at Guggenheim - TheFly